All In Biotech

Drug Trial Radar · NCT04455841

INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

84

Actual

Start

Mar 19, 2021

Primary completion

Apr 1, 2025

Study completion Sep 8, 2026

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
Jul 2, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and expansion.

Conditions

  • Anemia
  • Post-essential Thrombocythemia Myelofibrosis
  • Post-polycythemia Vera Myelofibrosis

Interventions

  • INCB000928Drug

    INCB000928 will be administered at protocol defined dose.

  • ruxolitinibDrug

    Ruxolitinib will be administered at protocol defined dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Treatment-emergent Serious Adverse Event (SAE)Time frame: up to approximately 4 years
  2. Number of Participants With Any ≥Grade 3 TEAE and Any Treatment-emergent SAETime frame: up to approximately 4 years
  3. Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: from Cycle 1 Day 1 to Cycle 1 Day 28
  4. Maximum Tolerated Dose (MTD)Time frame: from Cycle 1 Day 1 to Cycle 1 Day 28
  5. Recommended Dose for Expansion (RDE)Time frame: from Cycle 1 Day 1 to Cycle 1 Day 28

Locations

34 sites in 6 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California

  • City of Hope Orange County

    Irvine, California

  • Usc Norris Comprehensive Cancer Center

    Los Angeles, California

  • Stanford Cancer Center

    Palo Alto, California

  • Prebys Cancer Center

    San Diego, California

  • Emory University - Winship Cancer Institute

    Atlanta, Georgia

  • Emory University-Winship Cancer Institute

    Atlanta, Georgia

  • Start Midwest

    Grand Rapids, Michigan

  • Washington University School of Medicine

    St Louis, Missouri

  • Weill Cornell Medical Centers

    New York, New York

  • Duke University Medical Center, Department of Hematologic Malignancies and Cellular Therapy

    Durham, North Carolina

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Md Anderson Cancer Center

    Houston, Texas

  • Princess Margaret Cancer Center

    Toronto, Ontario, Canada

  • McGill University Jewish General Hospital

    Montreal, Quebec, Canada

  • Centre Hospitalier D'Angers

    Angers, France

  • Institut Paoli Calmettes

    Marseille, France

  • Hospital Saint Louis

    Paris, France

  • Azienda Ospedaliera Papa Giovanni Xxiii

    Bergamo, Italy

  • S Orsolas University Hospital Seragnoli Institute of Hematology

    Bologna, Italy

  • Azienda Ospedaliero-Universitaria Careggi (Aouc)

    Florence, Italy

  • Azienda Ospedaliera Universitaria San Luigi Gonzaga Orbassano

    Orbassano, Italy

  • Comitato Di Bioetica Della Fondazione Irccs Policlinico San Matteo

    Pavia, Italy

  • Ospedale Santa Maria Della Misericordia Perugia

    Perugia, Italy

  • Tokyo Medical and Dental University Hospital

    Bunkyō City, Japan

  • Chiba Cancer Center

    Chiba, Japan

  • Gifu Municipal Hospital

    Gifu, Japan

  • Kansai Medical University Hospital

    Hirakata, Japan

  • Kumamoto Shinto General Hospital

    Kumamoto, Japan

  • Osaka International Cancer Institute

    Osaka, Japan

  • United Lincolnshire Hospitals

    Boston, United Kingdom

  • Lincoln County Hospital

    Lincoln, United Kingdom

  • Royal Cornwall Hospital Truro Sunrise Centre

    Truro, United Kingdom

  • University Hospital of Wales

    Cardiff, WLS, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.